Encompass Health CEO Mark Tarr Engages in Routine Insider Sales to Cover Tax Liabilities – No Market Shock Expected
Mark Tarr’s 2,488‑share sale at $106.15 shows routine tax‑covering trading, not a red flag, and offers investors insight into Encompass Health’s insider liquidity and long‑term outlook.
4 minutes to read

